NEW YORK (360Dx) – Evercore ISI today upgraded its ratings for shares of Quest Diagnostics to Outperform from In Line, and raised the target price to $121 from $108, as tax changes and new insurance contracts are expected to lessen the impact of lower Medicare prices for lab tests under the Protecting Access to Medicare Act.